deaminooxytocin profile

demoxytocin : A heterodetic cyclic peptide that is the synthetic analog of the peptide hormone oxytocin where the free amino group in the half-cystine residue is replaced by hydrogen. The mechanism of action and pharmacological properties of demoxytocin and oxytocin are similar. The drug affects the permeability of the cell membrane, increasing the content of calcium ions in smooth muscle cells, thereby increasing its contraction. It stimulates the contraction of smooth muscles of the uterus, as well as stimulating the contraction of myoepithelial cells of the mammary gland, and enhances the secretion of milk. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

deaminooxytocin: octa-peptide lacking free amino group on cystine residue; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	449224
CHEMBL ID	439044
CHEBI ID	135900
SCHEMBL ID	38442
MeSH ID	M0045897
PubMed CID	13242839
CHEMBL ID	435716
MeSH ID	M0045897

Synonym
113-78-0
1-(3-mercaptopropionic acid)-oxytocin
oda-914
demoxytocin [inn]
desaminooxytocin
demoxytocine [inn-french]
demossitocina [dcit]
sandopart
demoxitocina [inn-spanish]
demoxytocinum [inn-latin]
demoxytocin
oda 914
einecs 204-034-9
CHEBI:135900
sandopral
1-{[(4r,7s,10s,13s,16s)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2s)-butan-2-yl]-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-l-prolyl-l-leucylglycinamide
demoxytocine
demoxytocinum
demoxitocina
desamino-oxytocin
desamino oxytocin
odeax
(2s)-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(4r,7s,10s,13s,16s)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2s)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan
CHEMBL439044 ,
oxytocin, deamino-
1-deaminooxytocin
demossitocina
2n9hm3x95f ,
unii-2n9hm3x95f
SCHEMBL38442
deaminooxytocin [mi]
1-(3-mercaptopropionic acid)oxytocin
demoxytocin [who-dd]
oxytocin, 1-(3-mercaptopropanoic acid)-
demoxytocin [mart.]
oxytocin, 1-(3-mercaptopropionic acid)-
bdbm50044676
Q5256388
DB13798
DTXSID701016964
CS-0109362
HY-P2168
deaminooxytocin
CHEMBL435716 ,
bdbm50056796
(2s)-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(4s,7s,10s,13s,16s)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2s)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan

Excerpt	Relevance	Reference
" Many investigations have shown that these prostaglandins are effective, and within certain dosage schedules, safe oxytocics, even though the systemic administration is accompanied by side effects, mainly from the gastro-intestinal tract."	( Labor induction with prostaglandins. Lange, AP; Pedersen, GT; Secher, NJ; Westergaard, JG, 1983)	0.27
" Relative to oxytocin, [5-t-BuPro(7)]oxytocin and [Mpa(1),5-t-BuPro(7)]oxytocin exhibited strongly reduced binding affinity to the receptor; however, both peptides maintained the pharmacophore characteristics responsible for signal transfer evoking the same maximal response as oxytocin in the single-dose procedure and exhibiting partial agonistic activity in the cumulative dose-response procedure."	( A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys(6)-Pro(7) amide cis-isomer population. Bélec, L; Lubell, WD; Slaninova, J, 2000)	0.31

Role	Description
oxytocic	A drug that stimulates contraction of the myometrium. Oxytocics are used to induce labour, obstetric at term, to prevent or control postpartum or postabortion haemorrhage, and to assess foetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (abortifacients).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
heterodetic cyclic peptide	A heterodetic cyclic peptide is a peptide consisting only of amino-acid residues, but in which the linkages forming the ring are not solely peptide bonds; one or more is an isopeptide, disulfide, ester, or other bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Oxytocin receptor	Homo sapiens (human)	Ki	0.0003	0.0001	0.0718	0.9780	AID1306778
Vasopressin V1a receptor	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0006	0.3835	2.0000	AID1178653
Oxytocin receptor	Rattus norvegicus (Norway rat)	Ki	0.0020	0.0009	0.0489	0.2300	AID151927; AID223652
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Vasopressin V2 receptor	Homo sapiens (human)	EC50 (µMol)	0.0035	0.0000	0.5506	6.7000	AID1178647
Oxytocin receptor	Homo sapiens (human)	EC50 (µMol)	0.0000	0.0000	0.0805	0.8810	AID1178646; AID1306776; AID1370595; AID1450439
Vasopressin V1a receptor	Homo sapiens (human)	EC50 (µMol)	0.0191	0.0000	0.1971	3.2000	AID1178648; AID1370597; AID1450440; AID1450441
Vasopressin V1b receptor	Homo sapiens (human)	EC50 (µMol)	0.1800	0.0000	0.0360	0.2400	AID1178649
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
positive regulation of systemic arterial blood pressure	Vasopressin V2 receptor	Homo sapiens (human)
renal water retention	Vasopressin V2 receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Vasopressin V2 receptor	Homo sapiens (human)
activation of adenylate cyclase activity	Vasopressin V2 receptor	Homo sapiens (human)
hemostasis	Vasopressin V2 receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Vasopressin V2 receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Vasopressin V2 receptor	Homo sapiens (human)
positive regulation of gene expression	Vasopressin V2 receptor	Homo sapiens (human)
telencephalon development	Vasopressin V2 receptor	Homo sapiens (human)
response to cytokine	Vasopressin V2 receptor	Homo sapiens (human)
positive regulation of intracellular signal transduction	Vasopressin V2 receptor	Homo sapiens (human)
cellular response to hormone stimulus	Vasopressin V2 receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Vasopressin V2 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Vasopressin V2 receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by vasopressin	Vasopressin V2 receptor	Homo sapiens (human)
suckling behavior	Oxytocin receptor	Homo sapiens (human)
response to amphetamine	Oxytocin receptor	Homo sapiens (human)
muscle contraction	Oxytocin receptor	Homo sapiens (human)
cell surface receptor signaling pathway	Oxytocin receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Oxytocin receptor	Homo sapiens (human)
heart development	Oxytocin receptor	Homo sapiens (human)
lactation	Oxytocin receptor	Homo sapiens (human)
memory	Oxytocin receptor	Homo sapiens (human)
response to xenobiotic stimulus	Oxytocin receptor	Homo sapiens (human)
positive regulation of norepinephrine secretion	Oxytocin receptor	Homo sapiens (human)
telencephalon development	Oxytocin receptor	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Oxytocin receptor	Homo sapiens (human)
response to estradiol	Oxytocin receptor	Homo sapiens (human)
response to progesterone	Oxytocin receptor	Homo sapiens (human)
response to anoxia	Oxytocin receptor	Homo sapiens (human)
response to cytokine	Oxytocin receptor	Homo sapiens (human)
social behavior	Oxytocin receptor	Homo sapiens (human)
response to cocaine	Oxytocin receptor	Homo sapiens (human)
maternal behavior	Oxytocin receptor	Homo sapiens (human)
sperm ejaculation	Oxytocin receptor	Homo sapiens (human)
eating behavior	Oxytocin receptor	Homo sapiens (human)
response to peptide hormone	Oxytocin receptor	Homo sapiens (human)
estrous cycle	Oxytocin receptor	Homo sapiens (human)
positive regulation of blood pressure	Oxytocin receptor	Homo sapiens (human)
digestive tract development	Oxytocin receptor	Homo sapiens (human)
positive regulation of synapse assembly	Oxytocin receptor	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Oxytocin receptor	Homo sapiens (human)
positive regulation of penile erection	Oxytocin receptor	Homo sapiens (human)
ERK1 and ERK2 cascade	Oxytocin receptor	Homo sapiens (human)
positive regulation of uterine smooth muscle contraction	Oxytocin receptor	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Oxytocin receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Oxytocin receptor	Homo sapiens (human)
female pregnancy	Oxytocin receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by vasopressin	Oxytocin receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Oxytocin receptor	Homo sapiens (human)
maternal process involved in parturition	Oxytocin receptor	Homo sapiens (human)
cellular response to hormone stimulus	Oxytocin receptor	Homo sapiens (human)
maternal aggressive behavior	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of systemic arterial blood pressure	Vasopressin V1a receptor	Homo sapiens (human)
generation of precursor metabolites and energy	Vasopressin V1a receptor	Homo sapiens (human)
activation of phospholipase C activity	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Vasopressin V1a receptor	Homo sapiens (human)
negative regulation of female receptivity	Vasopressin V1a receptor	Homo sapiens (human)
grooming behavior	Vasopressin V1a receptor	Homo sapiens (human)
blood circulation	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of heart rate	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of glutamate secretion	Vasopressin V1a receptor	Homo sapiens (human)
myotube differentiation	Vasopressin V1a receptor	Homo sapiens (human)
calcium-mediated signaling	Vasopressin V1a receptor	Homo sapiens (human)
telencephalon development	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of cell growth	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of prostaglandin biosynthetic process	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of cellular pH reduction	Vasopressin V1a receptor	Homo sapiens (human)
social behavior	Vasopressin V1a receptor	Homo sapiens (human)
cellular response to water deprivation	Vasopressin V1a receptor	Homo sapiens (human)
maternal behavior	Vasopressin V1a receptor	Homo sapiens (human)
sperm ejaculation	Vasopressin V1a receptor	Homo sapiens (human)
response to corticosterone	Vasopressin V1a receptor	Homo sapiens (human)
negative regulation of transmission of nerve impulse	Vasopressin V1a receptor	Homo sapiens (human)
transport across blood-brain barrier	Vasopressin V1a receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Vasopressin V1a receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Vasopressin V1a receptor	Homo sapiens (human)
cellular response to hormone stimulus	Vasopressin V1a receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by vasopressin	Vasopressin V1a receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Vasopressin V1b receptor	Homo sapiens (human)
activation of phospholipase C activity	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of phospholipase A2 activity	Vasopressin V1b receptor	Homo sapiens (human)
regulation of cell population proliferation	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Vasopressin V1b receptor	Homo sapiens (human)
symbiont entry into host cell	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of inositol phosphate biosynthetic process	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of arachidonic acid secretion	Vasopressin V1b receptor	Homo sapiens (human)
transport across blood-brain barrier	Vasopressin V1b receptor	Homo sapiens (human)
cellular response to hormone stimulus	Vasopressin V1b receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by vasopressin	Vasopressin V1b receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Vasopressin V1b receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
vasopressin receptor activity	Vasopressin V2 receptor	Homo sapiens (human)
protein binding	Vasopressin V2 receptor	Homo sapiens (human)
peptide binding	Vasopressin V2 receptor	Homo sapiens (human)
peptide hormone binding	Oxytocin receptor	Homo sapiens (human)
peptide binding	Oxytocin receptor	Homo sapiens (human)
vasopressin receptor activity	Oxytocin receptor	Homo sapiens (human)
oxytocin receptor activity	Oxytocin receptor	Homo sapiens (human)
vasopressin receptor activity	Vasopressin V1a receptor	Homo sapiens (human)
protein kinase C binding	Vasopressin V1a receptor	Homo sapiens (human)
protein binding	Vasopressin V1a receptor	Homo sapiens (human)
peptide hormone binding	Vasopressin V1a receptor	Homo sapiens (human)
V1A vasopressin receptor binding	Vasopressin V1a receptor	Homo sapiens (human)
peptide binding	Vasopressin V1a receptor	Homo sapiens (human)
vasopressin receptor activity	Vasopressin V1b receptor	Homo sapiens (human)
protein kinase C binding	Vasopressin V1b receptor	Homo sapiens (human)
peptide binding	Vasopressin V1b receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endosome	Vasopressin V2 receptor	Homo sapiens (human)
endoplasmic reticulum	Vasopressin V2 receptor	Homo sapiens (human)
Golgi apparatus	Vasopressin V2 receptor	Homo sapiens (human)
plasma membrane	Vasopressin V2 receptor	Homo sapiens (human)
membrane	Vasopressin V2 receptor	Homo sapiens (human)
endocytic vesicle	Vasopressin V2 receptor	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Vasopressin V2 receptor	Homo sapiens (human)
perinuclear region of cytoplasm	Vasopressin V2 receptor	Homo sapiens (human)
plasma membrane	Vasopressin V2 receptor	Homo sapiens (human)
plasma membrane	Oxytocin receptor	Homo sapiens (human)
microvillus	Oxytocin receptor	Homo sapiens (human)
adherens junction	Oxytocin receptor	Homo sapiens (human)
apical plasma membrane	Oxytocin receptor	Homo sapiens (human)
plasma membrane	Oxytocin receptor	Homo sapiens (human)
endosome	Vasopressin V1a receptor	Homo sapiens (human)
plasma membrane	Vasopressin V1a receptor	Homo sapiens (human)
endocytic vesicle	Vasopressin V1a receptor	Homo sapiens (human)
plasma membrane	Vasopressin V1a receptor	Homo sapiens (human)
endosome	Vasopressin V1b receptor	Homo sapiens (human)
Golgi apparatus	Vasopressin V1b receptor	Homo sapiens (human)
plasma membrane	Vasopressin V1b receptor	Homo sapiens (human)
plasma membrane	Vasopressin V1b receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (65)

Assay ID	Title	Year	Journal	Article
AID1151058	Antidiuretic activity in rat	1976	Journal of medicinal chemistry, Jun, Volume: 19, Issue:6	Oxytocin analogues with combined high smooth muscle and negligible antidiuretic activities. Investigation of position 7 in neurohypophyseal hormones.
AID1178651	Selectivity ratio of EC50 for human vasopressin V1a expressed in HEK293 cells to EC50 for human oxytocin receptor expressed in CHO-K1 cells	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID1178647	Agonist activity at human vasopressin V2 expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID1370598	Agonist activity at human OTR expressed in CHO cells assessed as increase in calcium flux after 60 to 120 mins by fluo-4 dye based FLIPR assay relative to control	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Hybrid peptide-small molecule oxytocin analogs are potent and selective agonists of the oxytocin receptor.
AID1178656	Clearance in Sprague-Dawley rat at 0.2 mg/kg, iv administered in cassette mode as bolus dose	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID1450439	Agonist activity at human OTR expressed in CHO cells assessed as calcium mobilization measured after 30 mins by Fluo-4-AM dye based FLIPR assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Potent and selective oxytocin receptor agonists without disulfide bridges.
AID1370596	Stability in human liver microsomes by LC/MS/MS analysis	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Hybrid peptide-small molecule oxytocin analogs are potent and selective agonists of the oxytocin receptor.
AID1306777	Intrinsic agonist activity at human oxytocin receptor expressed in CHO cells assessed as increase in intracellular calcium flux measured for 90 sec by fluo-4 dye based FLIPR assay relative to control	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Systematic N-methylation of oxytocin: Impact on pharmacology and intramolecular hydrogen bonding network.
AID1150194	Induction of vasodepressor activity in conscious chicken	1976	Journal of medicinal chemistry, Jul, Volume: 19, Issue:7	Synthesis and some pharmacological properties of oxytocin analogues having L-thiazolidine-4-carboxylic acid in position 7.
AID1150193	Induction of oxytocic activity in rat uterus	1976	Journal of medicinal chemistry, Jul, Volume: 19, Issue:7	Synthesis and some pharmacological properties of oxytocin analogues having L-thiazolidine-4-carboxylic acid in position 7.
AID1151055	Activity at rat oxytocin receptor in rat uterus assessed as uterotonic activity	1976	Journal of medicinal chemistry, Jun, Volume: 19, Issue:6	Oxytocin analogues with combined high smooth muscle and negligible antidiuretic activities. Investigation of position 7 in neurohypophyseal hormones.
AID1450441	Agonist activity at human V1b receptor expressed in CHO cells assessed as calcium mobilization measured after 30 mins by Fluo-4-AM dye based FLIPR assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Potent and selective oxytocin receptor agonists without disulfide bridges.
AID1178659	Partial agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID1178646	Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID1178650	Selectivity ratio of EC50 for human vasopressin V2 expressed in HEK293 cells to EC50 for human oxytocin receptor expressed in CHO-K1 cells	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID1178648	Agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID1450440	Agonist activity at human V1a receptor expressed in CHO cells assessed as calcium mobilization measured after 30 mins by Fluo-4-AM dye based FLIPR assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Potent and selective oxytocin receptor agonists without disulfide bridges.
AID1450442	Selectivity ratio of EC50 for human V1a receptor to EC50 for human OTR	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Potent and selective oxytocin receptor agonists without disulfide bridges.
AID1151059	Pressor activity in rat	1976	Journal of medicinal chemistry, Jun, Volume: 19, Issue:6	Oxytocin analogues with combined high smooth muscle and negligible antidiuretic activities. Investigation of position 7 in neurohypophyseal hormones.
AID1178652	Selectivity ratio of EC50 for human vasopressin V1b expressed in HEK293 cells to EC50 for human oxytocin receptor expressed in CHO-K1 cells	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID1306778	Displacement of [3H]8-arginine-vasopressin from human oxytocin receptor expressed in CHO cell membrane incubated for 1 hr by liquid scintillation counting method	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Systematic N-methylation of oxytocin: Impact on pharmacology and intramolecular hydrogen bonding network.
AID1370597	Agonist activity at vasopressin 1a receptor (unknown origin)	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Hybrid peptide-small molecule oxytocin analogs are potent and selective agonists of the oxytocin receptor.
AID1151056	Induction of oxytocic activity in rabbit assessed as milk ejection	1976	Journal of medicinal chemistry, Jun, Volume: 19, Issue:6	Oxytocin analogues with combined high smooth muscle and negligible antidiuretic activities. Investigation of position 7 in neurohypophyseal hormones.
AID1370595	Agonist activity at human OTR expressed in CHO cells assessed as increase in calcium flux after 60 to 120 mins by fluo-4 dye based FLIPR assay	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Hybrid peptide-small molecule oxytocin analogs are potent and selective agonists of the oxytocin receptor.
AID1178649	Agonist activity at human vasopressin V1b expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID1178653	Antagonist activity at human vasopressin V1a expressed in AVP-stimulated HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID1178663	Partial agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay relative to control	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	New, potent, and selective peptidic oxytocin receptor agonists.
AID1151057	Induction of vasodepressor activity in conscious chicken	1976	Journal of medicinal chemistry, Jun, Volume: 19, Issue:6	Oxytocin analogues with combined high smooth muscle and negligible antidiuretic activities. Investigation of position 7 in neurohypophyseal hormones.
AID1450443	Selectivity ratio of EC50 for human V1b receptor to EC50 for human OTR	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Potent and selective oxytocin receptor agonists without disulfide bridges.
AID1306776	Agonist activity at human oxytocin receptor expressed in CHO cells assessed as increase in intracellular calcium flux measured for 90 sec by fluo-4 dye based FLIPR assay	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Systematic N-methylation of oxytocin: Impact on pharmacology and intramolecular hydrogen bonding network.
AID1150195	Effect on pressor activity in rat	1976	Journal of medicinal chemistry, Jul, Volume: 19, Issue:7	Synthesis and some pharmacological properties of oxytocin analogues having L-thiazolidine-4-carboxylic acid in position 7.
AID230138	Tested for the ratio of uterotonic potency to pressor potency(O/P)	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID176218	Effective dose was evaluated for the pressor activity in the dose range 2 x 10e -5-2 x 10e -4 mg/kg of rat	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys(6)-Pro(7) amide cis-isomer population.
AID151927	Binding affinity against Oxytocin receptor was determined in rat uterine membrane using radioligand [3H]oxytocin	1997	Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6	Synthesis and pharmacology of novel analogues of oxytocin and deaminooxytocin: directed methods for the construction of disulfide and trisulfide bridges in peptides.
AID294434	Agonist activity in rat uterus by uterotonic assay	2007	European journal of medicinal chemistry, Jun, Volume: 42, Issue:6	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
AID1150413	Activity at oxytocin receptor in rat uterus	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-
AID1137271	Agonist activity at oxytocin receptor (unknown origin)	1979	Journal of medicinal chemistry, Jan, Volume: 22, Issue:1	[1-Penicillamine,2-leucine]oxytocin. Synthesis and pharmacological and conformational studies of a potent peptide hormone inhibitor.
AID230134	Tested for the ratio of uterotonic potency to antidiuretic potency(O/A)	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID1149618	Antidiuretic activity in rat	1977	Journal of medicinal chemistry, Apr, Volume: 20, Issue:4	Pharmacological effects of introducing a double bond into a binding site of oxytocin. Analogues with L-3,4-dehydroproline in position 7.
AID1144696	Agonist activity at oxytocin receptor in rat uterus	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Synthesis and some pharmacological properties of five analogs of oxytocin having L-homocysteine in position 6.
AID169130	Biological activity was determined by pressor test using pithed rat preparations	1997	Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6	Synthesis and pharmacology of novel analogues of oxytocin and deaminooxytocin: directed methods for the construction of disulfide and trisulfide bridges in peptides.
AID1148686	Vasopressor activity in iv dosed phenoxybenzamine treated rat	1978	Journal of medicinal chemistry, Sep, Volume: 21, Issue:9	Design of potent antagonists of the vasopressor response to arginine-vasopressin.
AID1150420	Ratio of activity at oxytocin receptor in rat uterus to vasopressor activity in rat	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-
AID1144698	Agonist activity at oxytocin receptor in chicken by avian vasodepressor assay	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Synthesis and some pharmacological properties of five analogs of oxytocin having L-homocysteine in position 6.
AID171775	Uterotonic activity in vitro in isolated rat uterus in absence of magnesium	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID1148688	Antidiuretic activity in iv dosed rat	1978	Journal of medicinal chemistry, Sep, Volume: 21, Issue:9	Design of potent antagonists of the vasopressor response to arginine-vasopressin.
AID1150414	Activity at oxytocin receptor in rat uterus in presence of 0.5 mM Mg2+	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-
AID1149619	Pressor activity in rat	1977	Journal of medicinal chemistry, Apr, Volume: 20, Issue:4	Pharmacological effects of introducing a double bond into a binding site of oxytocin. Analogues with L-3,4-dehydroproline in position 7.
AID1149616	Activity at uterotonic receptor in rat uterus assessed as uterotonic activity	1977	Journal of medicinal chemistry, Apr, Volume: 20, Issue:4	Pharmacological effects of introducing a double bond into a binding site of oxytocin. Analogues with L-3,4-dehydroproline in position 7.
AID190050	In Vitro evaluation for the uterotonic activity in rat in the absence of Magnesium	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys(6)-Pro(7) amide cis-isomer population.
AID168538	Tested for vasopressor activity in rat	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID1150417	Oxytocic activity in rabbit assessed as milk ejection	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-
AID190022	Compound was evaluated for the pressor activity	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys(6)-Pro(7) amide cis-isomer population.
AID1150419	Antidiuretic activity in rat	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-
AID169132	Biological activity was determined by uterotonic in vitro test in magnesium-free solution	1997	Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6	Synthesis and pharmacology of novel analogues of oxytocin and deaminooxytocin: directed methods for the construction of disulfide and trisulfide bridges in peptides.
AID223652	Binding affinity against oxytocin receptor	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys(6)-Pro(7) amide cis-isomer population.
AID294437	Antagonist activity in phenoxybenzamine-treated rat by Pressor assay	2007	European journal of medicinal chemistry, Jun, Volume: 42, Issue:6	Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
AID190051	In Vitro evaluation for the uterotonic activity in rat in the presence of 1 mM of Magnesium	2000	Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8	A study of the relationship between biological activity and prolyl amide isomer geometry in oxytocin using 5-tert-butylproline to augment the Cys(6)-Pro(7) amide cis-isomer population.
AID1150418	Vasopressor activity in rat	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-
AID1144700	Agonist activity at oxytocin receptor in rat assessed as pressor response	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Synthesis and some pharmacological properties of five analogs of oxytocin having L-homocysteine in position 6.
AID169134	Biological activity was determined by uterotonic in vivo test using urethane-anesthetized rats (protracted action)	1997	Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6	Synthesis and pharmacology of novel analogues of oxytocin and deaminooxytocin: directed methods for the construction of disulfide and trisulfide bridges in peptides.
AID1150421	Ratio of activity at oxytocin receptor in rat uterus to antidiuretic activity in rat	1976	Journal of medicinal chemistry, Mar, Volume: 19, Issue:3	Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-
AID168372	Tested for antidiuretic activity in rat	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID171590	The compound was tested for milk ejection activity in rat	1983	Journal of medicinal chemistry, Apr, Volume: 26, Issue:4	Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
AID1149617	Vasodepressor activity in fowl	1977	Journal of medicinal chemistry, Apr, Volume: 20, Issue:4	Pharmacological effects of introducing a double bond into a binding site of oxytocin. Analogues with L-3,4-dehydroproline in position 7.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	34 (75.56)	18.7374
1990's	3 (6.67)	18.2507
2000's	3 (6.67)	29.6817
2010's	5 (11.11)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Trials	3 (6.98%)	5.53%
Reviews	0 (0.00%)	6.00%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
Other	40 (93.02%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	3.26	6	0	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
arginine vasopressin Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.	2.1	1	0	vasopressin	cardiovascular drug; hematologic agent; mitogen
deamino arginine vasopressin Deamino Arginine Vasopressin: A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.	2.1	1	0	heterodetic cyclic peptide	diagnostic agent; renal agent; vasopressin receptor agonist
carbetocin carbetocin : Oxytocin in which the hydrogen on the phenolic hydroxy group is substituted by methyl, the amino group on the cysteine residue is substituted by hydrogen, and the sulfur of the cysteine residue is replaced by a methylene group. A synthetic carba-analogue of oxytocin, it is used to control bleeding after giving birth. Like oxytocin, it causes contraction of the uterus.	2.1	1	0	heterodetic cyclic peptide	oxytocic
way 267464 [no description available]	2.15	1	0
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	1.96	1	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
phenol [no description available]	2.01	1	0	phenols	antiseptic drug; disinfectant; human xenobiotic metabolite; mouse metabolite
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.01	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	1.93	1	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
tryptophan Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.	2.01	1	0	erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan	antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
thiolactic acid thiolactic acid: RN given refers to parent cpd	1.99	1	0	mercaptopropanoic acid
argipressin, beta-mercapto-beta,beta cyclopentamethylenepropionic acid(1)- [no description available]	1.97	1	0
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	7.25	39	3	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
diethylstilbestrol Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed). diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups.	1.95	1	0	olefinic compound; polyphenol	antifungal agent; antineoplastic agent; autophagy inducer; calcium channel blocker; carcinogenic agent; EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; endocrine disruptor; xenoestrogen
lypressin Lypressin: The porcine antidiuretic hormone (VASOPRESSINS). It is a cyclic nonapeptide that differs from ARG-VASOPRESSIN by one amino acid, containing a LYSINE at residue 8 instead of an ARGININE. Lys-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.	2.36	2	0	cyclic peptide
arginine vasopressin Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.	2.87	4	0	vasopressin	cardiovascular drug; hematologic agent; mitogen
alpha-chymotrypsin Chymotrypsin: A serine endopeptidase secreted by the pancreas as its zymogen, CHYMOTRYPSINOGEN and carried in the pancreatic juice to the duodenum where it is activated by TRYPSIN. It selectively cleaves aromatic amino acids on the carboxyl side.	1.93	1	0
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	5.36	5	3	prostaglandins E	human metabolite; mouse metabolite; oxytocic
atosiban [no description available]	2.03	1	0	oligopeptide
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	1.99	1	0	cysteinium	fundamental metabolite
pituitrin Pituitrin: A substance or extract from the neurohypophysis (PITUITARY GLAND, POSTERIOR).	2.39	2	0
vasopressin, 1-deamino-4-val-8-arg- [no description available]	1.95	1	0
fertinex [no description available]	1.95	1	0

Condition	Relationship Strength	Studies	Trials
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	6.6	20	3
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	2.86	4	0
Premature Rupture of Fetal Membranes [description not available]	3.35	1	1
Fetal Membranes, Premature Rupture Spontaneous tearing of the membranes surrounding the FETUS any time before the onset of OBSTETRIC LABOR. Preterm PROM is membrane rupture before 37 weeks of GESTATION.	3.35	1	1
Icterus Gravis Neonatorum [description not available]	1.95	1	0
Jaundice, Neonatal Yellow discoloration of the SKIN; MUCOUS MEMBRANE; and SCLERA in the NEWBORN. It is a sign of NEONATAL HYPERBILIRUBINEMIA. Most cases are transient self-limiting (PHYSIOLOGICAL NEONATAL JAUNDICE) occurring in the first week of life, but some can be a sign of pathological disorders, particularly LIVER DISEASES.	1.95	1	0
Edema-Proteinuria-Hypertension Gestosis [description not available]	1.95	1	0
Pregnancy, Prolonged A term used to describe pregnancies that exceed the upper limit of a normal gestational period. In humans, a prolonged pregnancy is defined as one that extends beyond 42 weeks (294 days) after the first day of the last menstrual period (MENSTRUATION), or birth with gestational age of 41 weeks or more.	1.95	1	0
Pre-Eclampsia A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.	1.95	1	0

deaminooxytocin

Description

Cross-References

Synonyms (46)

Research Excerpts

Dosage Studied

Roles (1)

Drug Classes (1)

Protein Targets (5)

Inhibition Measurements

Activation Measurements

Biological Processes (69)

Molecular Functions (7)

Ceullar Components (11)

Bioassays (65)

Research

Studies (45)

Market Indicators

Research Demand Index: 12.38

Study Types

deaminooxytocin

Description

Cross-References

Synonyms (46)

Research Excerpts

Dosage Studied

Roles (1)

Drug Classes (1)

Protein Targets (5)

Inhibition Measurements

Activation Measurements

Biological Processes (69)

Molecular Functions (7)

Ceullar Components (11)

Bioassays (65)

Research

Studies (45)

Market Indicators

Research Demand Index: 12.38

Study Types

Related Drugs (23)

Related Conditions (9)